XML 57 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
AGREEMENT WITH PDL BIOPHARMA, INC. (Details Narrative)
 3 Months Ended 6 Months Ended
Oct. 07, 2015
Number
$ / shares
Jun. 30, 2015
USD ($)
Jun. 26, 2015
USD ($)
Number
$ / shares
shares
Jun. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Dec. 31, 2015
USD ($)
Fair value           $ 168,805
Minimum cash balance required under existing loan documents       $ 2,000,000 $ 2,000,000  
Restricted cash       3,250,000 3,250,000 $ 3,250,000
PDL BioPharma, Inc (Administrative Agent and Lender) [Member]            
Debt face amount     $ 40,000,000      
Description of payment terms    

Interest only payments for the first eight interest payment dates and principal plus interest payments will commence on the ninth interest payment date. We may elect to pay a portion of the interest due in the form of additional loans (interest paid in kind) during the first eight interest payment dates.Each tranche will mature on the fifth anniversary of the date borrowed. We may elect to prepay the Loans at any time without any premium or penalty, subject to certain conditions.

      
Description of collateral    

Secured by a pledge of substantially all of the assets of the Company and certain of its domestic subsidiaries.

      
Minimum cash balance required under existing loan documents     $ 3,250,000      
PDL BioPharma, Inc (Administrative Agent and Lender) [Member] | Warrants [Member]            
Number common stock called | shares     4,444,445      
Exercise price (in dollars per shares) | $ / shares     $ 0.45      
Warrant expiration date     Jun. 26, 2025      
Fair value     $ 1,257,778      
Amortized interest expense   $ 2,431   44,922 89,844  
Deferred financing costs       805,917 805,917  
Amortized deferred financing costs   $ 1,464   27,849 55,698  
PDL BioPharma, Inc (Administrative Agent and Lender) [Member] | Tranche One Debt [Member]            
Debt face amount     $ 20,000,000 20,000,000 20,000,000  
Description of debt milestone placement    

In the event that a milestone relating to the placement of 9,000 billable units occurs on or before October 31, 2015.

      
Interest rate     13.50%      
Number of billable units | Number     9,000      
Date of first required debt repyment     Jan. 08, 2018      
Debt periodic repayment     $ 1,666,667      
PDL BioPharma, Inc (Administrative Agent and Lender) [Member] | Tranche Two Debt [Member]            
Debt face amount     $ 20,000,000 $ 20,000,000 $ 20,000,000  
Description of debt milestone placement    

(i) the placement of 27,750 billable units and (ii) the Company recording earnings before interest, tax, depreciation, and amortization (EBITDA) of not less than $7,000,000 on an annualized basis for the three calendar month period prior to the funding (on or before June 30, 2017).

      
Interest rate     13.00%      
Number of billable units | Number     27,250      
Earning before interest, tax, depreciation, and amortization milestone     $ 7,000,000      
Increase of interest rate if default occurs     5.00%      
PDL BioPharma, Inc (Administrative Agent and Lender) - First Amendment [Member] | Warrants [Member]            
Exercise price (in dollars per shares) | $ / shares $ 0.45          
PDL BioPharma, Inc (Administrative Agent and Lender) - First Amendment [Member] | Tranche Two Debt [Member]            
Description of debt milestone placement

Tranche Two Milestone, which changed from a minimum of 27,750 billable units (defined as one unit for each room control platform and two units for each nurse station monitor) to 31,500 Bed Equivalent Units (defined as a billable unit plus 14 units for each head-end server operating as the communication center and fractional units for mobile assets as applicable). 

          
Number of billable units | Number 31,500          
PDL BioPharma, Inc (Administrative Agent and Lender) - Restated Amendment [Member] | Warrants [Member]            
Exercise price (in dollars per shares) | $ / shares $ 0.40